Evotec AG has received a €2.5 million milestone payment from Boehringer Ingelheim (BI) for the identification of a candidate compound in a joint research programme on cardiometabolic risk. This is BI’s seventh milestone payment to Evotec.
Evotec AG has received a €2.5 million milestone payment from Boehringer Ingelheim (BI) for the identification of a candidate compound in a joint research programme on cardiometabolic risk. This is BI’s seventh milestone payment to Evotec.